Clevudine University of Georgia/Abbott/Bukwang/Triangle/Yale University

Current Opinion in Investigational Drugs

Volumn 1, Issue 3, 2000, Pages 308-313

  Kocic, I ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYCYTIDINE; ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; CLEVUDINE; DRUG ANALOG; ELVUCITABINE; LAMIVUDINE; LOBUCAVIR; PENCICLOVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; ZALCITABINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTIOUS MONONUCLEOSIS; LIVER CARCINOGENESIS; NONHUMAN; REVIEW; STEATOSIS; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; EPSTEIN-BARR VIRUS INFECTIONS; HEPATITIS B; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033693129     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus
2. L-FMAU, a novel anti-HBV and anti-EBV agent
3. Use of 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
4. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-β-L-arabinofuranosyl uracil
5. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil
6. Bukwang codevelops hepatitis B drug with US doctors
7. Bukwang eyes commercialization of L-FMAU in 2002
8. Triangle Pharmaceuticals signs agreement to license L-FMAU from Bukwang Pharmaceuticals; Triangle adds potent hepatitis B inhibitor to its portfolio of antiviral drug candidates
9. Bukwang inks $140 million royalty deal for hepatitis drug
10. Inhibitory effect of 2'-fluoro-5-methyl-β-L-arabinofuranosyl-uracil on duck hepatitis B virus replication
11. International Society for Antiviral Research - 12th International Conference; Clinical Update on Antiviral Drugs, Jerusalem, Israel
12. Inhibition of hepatitis B virus by a novel L-nucleoside 2-fluoro-5-methyl-β-L-arabinofuranosyluracil
13. Pharmacokinetics of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil in woodchucks
14. Abbott Laboratories and Triangle Pharmaceuticals announce $335 million worldwide alliance to market six antiviral products
15. A practical synthesis of L-FMAU from L-arabinose
16. Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-β-L-arabinofuranosyl)-5-methyluracil 5'-triphosphate on Epstein-Barr virus and human DNA polymerases
17. Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase
18. Synthesis and antihepatitis B virus activity of 9-(2-deoxy-2-fluoro-β-L-arabinofuranosyl) purine nucleosides
19. Pharmacokinetics of 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats
20. Phase I trial of 1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl)-5-methyluracil (FMAU)
21. Epstein-Barr virus: Inhibition of replication by three new drugs
22. Potent antiviral 2'-fluoro-arabinosyl pyrimidine nucleosides: Lack of mutagenic activity
23. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
24. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent
25. L-FMAU. Anti-HBV, anti-EBV
26. Comparison of antiviral effects of mismatched double-stranded RNA and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-5-methyl-uracil (D-FMAU) against duck hepatitis B virus in vitro
27. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in rats
28. Structure-activity relationships of 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)pyrimidine nucleosides as antihepatitis B virus agents
29. Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl) uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection
30. Perspectives for the treatment of hepatitis B virus infections
31. ICN Pharmaceuticals to step up research and development efforts
32. Bukwang Pharm to develop antihepatitis agent
33. Triangle Pharmaceuticals
34. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
35. Phase I pharmacokinetic and safety evaluation of clevudine (L-FMAU), a new agent under development for the treatment of hepatitis B virus (HBV) infection